According tomedia BGR reported that the new coronavirus pandemic brought great sadness and pain. Over the past few months, researchers have worked tirelessly to find ways to limit transmission in the study of SARS-CoV-2. Various treatment options have been successfully used to save patients worldwide. Recovery plasma therapy has played a role, and antibody-based drugs are also in progress. Some vaccine trials are moving faster than we thought, and the world is optimistic about its chances of success. The work didn’t stop there, as researchers are still trying to figure out how to get the virus in the event once it is infected with the virus.
Scientists who have studied specific characteristics of drugs that may hinder the ability of viruses to replicate in cells have screened out seven existing human and animal drugs that may have an effect. The list includes the extremely common anti-anxiety drug, the anti-anxiety drug Xanax, as well as six other drugs, two of which have shown promising results in the laboratory.
Researchers from around Barcelona, Spain, are looking for existing drugs that can block the virus’s main protease (M-pro), which plays a key role in the entire replication process. The new coronavirus binds to cells through ACE2 receptors and takes over the cell’s manufacturing of replicas. Cells die in the process, and new copies of the virus can infect other cells nearby. Most people’s immune systems can fight with or without the help of drugs. But some people don’t fight disease well.
The team analyzed 6,466 licensed drugs to look for drugs that inhibit edgy m-pro enzymes. Knowridge reported that the researchers used computational screening to isolate approved drugs that could play a role in COVID-19 therapy. The study predicts that seven drugs can be used as inhibitors, including perampanel, carprofen, Celecoxib, Aprax, trovafloxacin, sarafloxacin and ethyl bison.
Some of them are pet medications. Appenylen is a common anti-anxiety drug. Double bean ethyl is suitable for the prevention and treatment of thrombosis embolism diseases. Previous studies have shown that COVID-19 can lead to severe blood clotting and can lead to life-threatening complications such as strokes and heart attacks. Both Quvale and Salasha are antibiotics, while Theranpanay is an anti-epileptic drug.
But researchers are currently testing kalofen and Ceresib, two nonsteroidal anti-inflammatory drugs (NSAIDs), in the lab. The only real difference between these drugs is that the former is used for animal medications. Interestingly, a few months ago, some doctors said that nonsteroidal anti-inflammatory drugs could be a risk factor for COVID-19, although subsequent studies have shown that this is not the case at all.
Researchers in Spain shared the results with the international initiative COVID Moonshot, who chose the NSAIDs for testing. It was found that the in vitro activity of M-pro was 11.90% and 3.97%, respectively, with a mere 50?M of Ceresib or carpofin inhibited. Both molecules could be used for treatment in the future, but more research is needed.
Knowridge said the rest of the drugs could be tested soon. In other words, there is no evidence that appenas may improve the condition of COVID-19 patients, nor is there any evidence that it can prevent serious outcomes, as do other drugs mentioned above.